◆英語タイトル:OncBioMune Pharmaceuticals Inc (OBMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8269
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
OncBioMune Pharmaceuticals Inc (OncBioMune), formerly Quint Media Inc is a biopharmaceutical company that develops novel cancer immunotherapy products. The company’s products comprise biosimilars and vaccines developed for cancer types such as renal, breast, prostrate, and ovarian cancer. Its lead products OvcaVax for treating ovarian cancer and ProscaVax, a therapeutic vaccine is developed for prostate cancer patients. OncBioMune also utilizes Targeted Transferrin Transport Technology to deliver cytotoxic agents targeted selectively to the cancer cell and reduce effect on normal cells. The company’s products attacks iron metabolism of cancer cells and prevent iron storage into the protein ferritin with its technology. It also has a portfolio of targeted therapies such as paclitaxel. OncBioMune is headquartered in Baton Rouge, Louisiana, the US.
OncBioMune Pharmaceuticals Inc (OBMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
OncBioMune Pharma Acquires Propolis Product Line from roha Arzneimittel 10
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 11
Venture Financing 12
Oncbiomune Pharma Raises USD0.01 Million in Financing Round 12
Partnerships 13
OncBioMune Pharma Selects Theradex Systems for Two Phase II Trials of ProscaVax 13
OncBioMune Pharma to Enter into Distribution Agreement with Lipomed 14
OncBioMune Pharma to Enter into Agreement with Gem Pharma 15
OncBioMune Pharma to Enter into Agreement with EOC Pharma 16
OncBioMune Pharma and Vitel Labs Forms Joint Venture 17
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 18
Equity Offering 19
OncBioMune Pharma Raises USD1.3 Million in Private Placement of Shares 19
OncBioMune Pharma to Raise USD10.1 Million in Private Placement of Shares 20
OncBioMune Pharma Raises USD0.1 Million in Private Placement of Shares 21
OncBioMune Pharma Raises Funds in Private Placement of Units 23
Acquisition 24
OncBioMune Pharma Acquires Vitel Labs 24
OncBioMune Pharmaceuticals Inc – Key Competitors 25
OncBioMune Pharmaceuticals Inc – Key Employees 26
OncBioMune Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Joint Venture 27
Recent Developments 28
Corporate Communications 28
Mar 19, 2018: OncBioMune Names Robert Neal Holcomb to Board of Directors 28
Product News 29
Jun 28, 2017: OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico 29
Other Significant Developments 30
Mar 27, 2017: OncBioMune Sales of Bekunis and Cirkused Exceed Forecast by 164 Percent in First Six Months on Market 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31
List of Tables
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncBioMune Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OncBioMune Pharma Acquires Propolis Product Line from roha Arzneimittel 10
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 11
Oncbiomune Pharma Raises USD0.01 Million in Financing Round 12
OncBioMune Pharma Selects Theradex Systems for Two Phase II Trials of ProscaVax 13
OncBioMune Pharma to Enter into Distribution Agreement with Lipomed 14
OncBioMune Pharma to Enter into Agreement with Gem Pharma 15
OncBioMune Pharma to Enter into Agreement with EOC Pharma 16
OncBioMune Pharma and Vitel Labs Forms Joint Venture 17
Apricus Biosciences Enters Into Co-Promotion Agreement With PediatRx For GRANISOL And AQUORAL 18
OncBioMune Pharma Raises USD1.3 Million in Private Placement of Shares 19
OncBioMune Pharma to Raise USD10.1 Million in Private Placement of Shares 20
OncBioMune Pharma Raises USD0.1 Million in Private Placement of Shares 21
OncBioMune Pharma Raises Funds in Private Placement of Units 23
OncBioMune Pharma Acquires Vitel Labs 24
OncBioMune Pharmaceuticals Inc, Key Competitors 25
OncBioMune Pharmaceuticals Inc, Key Employees 26
OncBioMune Pharmaceuticals Inc, Subsidiaries 27
OncBioMune Pharmaceuticals Inc, Joint Venture 27
List of Figures
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncBioMune Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8